EDAP Issues Letter to Shareholders
01 févr. 2022 08h00 HE
|
EDAP TMS S.A.
LYON, France, February 1, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders: To my...
EDAP Announces Publication of Positive Pre-clinical Results Using Intraoperative HIFU Ablation of the Pancreas in the Journal Cancers
13 janv. 2022 08h00 HE
|
EDAP TMS S.A.
Represents first step towards a potential clinical treatment of locally advanced pancreatic cancer LYON, France, January 13, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global...
EDAP Provides Corporate Update on US Focal One Installation Growth
05 janv. 2022 08h00 HE
|
EDAP TMS S.A.
Company announces several key U.S. Focal One installations during Q4 LYON, France, January 5, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based...
EDAP to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
29 nov. 2021 09h30 HE
|
EDAP TMS S.A.
LYON, France, November 29, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will participate in a fireside chat...
EDAP Reports Third Quarter 2021 Results and Provides Operational Update
17 nov. 2021 16h35 HE
|
EDAP TMS S.A.
Year-to-date revenue of approximately EUR 30.1 million (USD 35.9 million) increased 14.4% year-over-year Q3 revenue of EUR 9.4 million (USD 11.1 million), flat with Q3 2020, reflecting lingering...
EDAP TMS SA to Announce Third Quarter 2021 Financial Results on Wednesday, November 17, 2021
10 nov. 2021 08h00 HE
|
EDAP TMS S.A.
Company to host conference call and webcast on Thursday, November 18, at 8:30 am ET LYON, France, November 10, 2021 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound,...
EDAP Announces University of Washington Medicine to Launch Focal One® Robotic HIFU Program
28 sept. 2021 08h00 HE
|
EDAP TMS S.A.
Brings advanced focal ablation to prostate cancer patients in the Pacific Northwest LYON, France, September 28, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic...
EDAP Announces Presentation of Multiple Abstracts Favorably Comparing HIFU to Surgery at the American Urological Association 2021 Annual Meeting
14 sept. 2021 08h00 HE
|
EDAP TMS S.A.
Data demonstrate superiority of HIFU versus radical prostatectomy among prostate cancer patients LYON, France, September 14, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in...
EDAP to Participate at Upcoming Investor Conferences
07 sept. 2021 16h35 HE
|
EDAP TMS S.A.
LYON, France, September 7, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced that management will present at the following investor...
EDAP Reports Second Quarter 2021 Results and Provides Operational Update
25 août 2021 16h35 HE
|
EDAP TMS S.A.
Total revenue for the first half 2021 of EUR 20.7 million (USD $24.8 million) increased 22.5% over the same period of the prior year Net income was EUR 0.4 million (USD 0.4 million), or EUR 0.01 per...